BioMarin Reports Q4 2025 Earnings with Revenue Growth and Strategic Adjustments
BioMarin (BMRN) reported Q4 2025 earnings with total revenue of $875 million, a 17% year-over-year increase, driven by strong performance in enzyme therapies and Voxzogo. The company also announced a $240 million charge related to the strategic withdrawal of Roctavian, impacting fourth-quarter results.
Topics: Company Guidance Earnings Report Financial Performance Revenue Growth